Navigation Links
Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer
Date:4/6/2009

A Drug That Improves Survival Would Earn a 50 Percent Patient Share in the U.S. and a 40 Percent Patient Share in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., April 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in stage III prostate cancer. Clinical data and the opinions of interviewed thought leaders indicate that Sanofi-Aventis's Taxotere has advantages in this attribute over LHRH agonists, including Abbott's Lupron Depot, the sales-leading agent in the market.

The new report entitled Stage III Prostate Cancer: Oncologists Ready for New Type of Therapy finds that a drug that improves five-year disease-specific survival would earn a 50 percent patient share in stage III prostate cancer in the United States and a 40 percent patient share in Europe, according to surveyed U.S. and European oncologists.

In 2007, Decision Resources' proprietary clinical gold standard for stage III prostate cancer was Lupron Depot. Based on available data and expert opinion, Ferring Pharmaceuticals' degarelix will earn gold-standard status for stage III prostate cancer in 2012. Interviewed experts anticipate that degarelix, which has competitive advantages and has shown impressive Phase III clinical trial data, will be more effective than Lupron Depot.

"Interviewed experts are optimistic about the efficacy of some emerging agents in this market, most notably degarelix and Taxotere," said Decision Resources Analyst Natalia Reoutova. "In terms of improvements to survival, Taxotere, which has been approved for use in metastatic hormone-refractory prostate cancer, remains the most promising therapy for stage III prostate cancer and some interviewed physicians are already using it off-label."

About the Report

Stage III Prostate Cancer: Oncologists Ready for New Type of Therapy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                 Decision Resources, Inc.
    Christopher Comfort                Elizabeth Marshall
    781-296-2597                       781-296-2563
    ccomfort@dresources.com            emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
2. My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise
3. National Experts Offer Practical Tips for Parents Concerned about Autism
4. Covance Experts to Present Key Insights on Risk Management at Bio/Pharmaceutical Drug Safety Forum
5. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
6. Experts turn to Web to combat distressing skin disease
7. Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
8. Experts from Africa and Asia to Discuss Maternal Health in Live Online Chat
9. FDA Experts to Speak at RAPS Horizons Conference
10. Experts Revise Guidelines on Daily Aspirin for Heart
11. Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a company that ... product to the United States as part of its presence to expand its market ... aims to reduce the productions of nasty toxins as a result of drinking alcohol, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to take ... rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, ... Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... new medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two ...
(Date:1/20/2017)... ... ... Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift ... can be wheeled out of the way and stored when not in use. It is ... the feedback from customers into specific enhancements and created a new product that is built ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a ... percent pure essential oils, announced the company had a successful visit to the 2017 ... ECRM event gives companies that work in the nutritional, sports and health industries a ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... James Gilbart , ... 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... recently in a supplement to European Oncology & ... article by James Gilbart and ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange ... excited to announce that the first five replication ...  (RP:CB) have been published in eLife today. Despite ... represents the first practical evaluation of reproducibility rates ... reproducible studies. Unlike other assessments of reproducibility, the ...
Breaking Medicine Technology: